
analytical overview of pharmaceuticals companies in the U.S. Using the example of Pfizer along with Merck ( MRK ) , Novartis AG ( NVS ) and Sanofi ( SNY ) , will be enough to prove to you why this industry holds the key to a healthy portfolio. Brief
the opportunity outweighs the risk at this point. Novartis (NYSE: NVS ) remains an excellent investment, offering both ..... have to endure more punishment in the near-term as Novartis works through its issues (and Complete Story »
Novartis has one of the best drug pipelines in the industry.
owns only companies domiciled in the United States, which means that it doesn't invest in foreign behemoths such as Novartis NVS , Roche, and Sanofi-Aventis SNY. That said, many of the companies in VHT operate businesses spanning the globe
criteria eliminate foreign health-care companies, the index excludes international health-care behemoths such as Novartis NVS , GlaxoSmithKline GSK, Roche, and Sanofi-Aventis. That said, we'd note that most of the firms included here
capsules for the treatment of frequent heartburn. Shipments of the product to customers have already begun. This new product for the U.S. store brand market is the equivalent to Novartis ' ( NVS ) Prevacid 24 hour capsules. Post your comment!
regulatory hurdles for biosimilars will minimize competitor entry. Hospira, Teva TEVA, and Sandoz (a subsidiary of Novartis NVS ) lead the market for biosimilars in Europe, and Hospira hopes to be a leader in the nascent U.S. biosimilars market
largest generic pharmaceutical manufacturer, Mylan is a significant competitor. Teva TEVA, Sandoz (a subsidiary of Novartis NVS ), Mylan, and Watson WPI control an estimated 50% of the world generic market and are able to achieve greater economies
with India's drug regulators. Eli Lilly, along with other Big Pharma names such as GlaxoSmithKline ( GSK ) and Novartis ( NVS ) , has been colluding with Indian drug regulators to speed up approval procedures and put drugs on the Indian market
WASHINGTON, May 14 (Reuters) - U.S. health regulators said on Monday they could not definitively link Novartis AG 's multiple sclerosis pill Gilenya with the deaths of people who took the drug.